Global Health Giant Unveils Surprising Endorsement of Weight-Loss Drugs

On Thursday, the World Health Organization (WHO) declared its backing for weight-loss drugs in adults globally.

The group intends to support GLP-1 medications such as Wegovy and Zepbound for treatment purposes. obesity in adults As part of a change in strategy for tackling the worldwide obesity crisis, as reported by Reuters.

In a memorandum, the organization requested proposals to enhance accessibility to these drugs in nations classified as low- and middle-income, according to a summary by Reuters.

'OATZEMPIC' WEIGHT-LOSS DRINK: EFFECTIVENESS AND SAFETY EXPLORED

According to World Health Organization statistics, more than one billion people worldwide suffer from obesity, with approximately 70% residing in lower- and middle-income nations.

The demonstrated efficacy of weight-loss medications has prompted people, particularly those in the U.S. along with affluent nations such as Britain and Germany, to pursue GLP-1 treatments.

USE THE FOX NEWS APPLICATION

To read more Lifestyle articles, check this out https://smarthealthradar2025.blogspot.com//lifestyle

Expense can indeed play a role, since these drugs may cost over $1,000 each month, according to Reuters.

In a statement, a representative from the WHO mentioned that the organization has been developing “a series of new guidelines aimed at preventing, treating, and managing obesity across various age groups.” children, adolescents and adults.

CLICK HERE TO JOIN OUR LIFESTYLE NEWSLETTER

The organization stated it anticipates the medication guidelines will be concluded by August or September of 2025.

The guidance will also encompass "the methods and timing for this." class of medications The WHO indicated that it might be incorporated as a single element within a comprehensive chronic care framework encompassing both medical treatment and lifestyle modifications.

The WHO experts additionally intend to convene next week for determining whether GLP-1 medications ought to be added to the organization’s roster of crucial medicines aimed at tackling both obesity and type 2 diabetes.

The organization is apparently asking for longer-term studies Regarding the cost-efficiency of these medications "in every setting" and across various income levels.

Original article source: weight-loss medications receive an unexpected boost from a major worldwide health organization